Keller K A, Aggarwal S K
Toxicol Appl Pharmacol. 1983 Jun 30;69(2):245-56. doi: 10.1016/0041-008x(83)90305-8.
Cisplatin [cis-dichlorodiammineplatinum (II)], a broad spectrum antitumor agent, was tested for possible teratogenic and embryolethal effects on Wistar rats and Swiss Webster mice. Rats were given a single ip injection of 0.3, 1.0, 2.5, or 3.0 mg/kg cisplatin on Day 6, 8, 11, or 14 of gestation, whereas mice were given a single ip injection of 0.3, 3.0, 6.0, 8,0, or 13.0 mg/kg on Day 8 only. The embryonic LD50's in the rat were 2.88, 1.28, and 1.0 mg/kg for day 6, 8, and 11, respectively. There was no significant increase in embryolethality at any of the doses given on Day 14. The embryonic LD50 for mice was 5.24 mg/kg. An increase in the incidence of growth retardation or gross malformations was not discernable in the surviving fetuses with the number of dams used in this study. Cisplatin is highly embryolethal in rats and mice at dosages well below the adult therapeutic dosage in humans. This embryolethality is gestational stage-specific with the highest mortality corresponding to the period of rapid DNA replication in early organogenesis.
